Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ended
Participants planned
24
Countries
1
Sites
1
not applicable (submitted trial is bioavailability study in healthy subjects)
Key facts
- Sponsor
- Adamed Pharma S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 11 Oct 2023 → 4 Jan 2024
- Decision date (initial)
- 2023-10-02
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
not applicable (submitted trial is bioavailability study in healthy subjects)
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Adamed Pharma S.A.
- Sponsor organisation
- Adamed Pharma S.A.
- Address
- Ul. Mariana Adamkiewicza 6a, Pienkow Pienkow
- City
- Czosnow
- Postcode
- 05-152
- Country
- Poland
Scientific contact point
- Organisation
- Adamed Pharma S.A.
- Contact name
- Pharmacokinetic Study Team
Public contact point
- Organisation
- Adamed Pharma S.A.
- Contact name
- Pharmacokinetic Study Team
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Czechia | Ended | 24 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Czechia | 2023-10-11 | 2024-01-04 | 2023-10-11 | 2023-10-21 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2023-08-03 | Czechia | Acceptable 2023-09-15
|
2023-10-02 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2023-10-10 | Acceptable 2023-09-15
|